Biogen takes another blow as appeal for Tecfidera patent revival falls short

Despite Biogen's best efforts, Tecfidera generics are here to stay, it seems.

A U.S. appeals court has declined to resurrect a key patent on Biogen’s once-stalwart multiple sclerosis med Tecfidera, according to court documents filed Tuesday. It’s the latest spot of trouble for the struggling blockbuster, which succumbed to its first generic competitor in August 2020.